In 2018, Powell et al. developed the CRBN-based ALK degraders, TL13-12 and TL13-112, achieving the degradation of ALK fusion protein in NSCLC, ALCL, and neuroblastoma cell lines. Here, ALK is linked to non-small cell lung carcinoma.